Outlook Therapeutics Inc’s filing revealed that its Chief Financial Officer KENYON LAWRENCE A acquired Company’s shares for reported $28446.0 on Sep 26 ’24. In the deal valued at $5.69 per share,5,000 shares were bought. As a result of this transaction, KENYON LAWRENCE A now holds 5,946 shares worth roughly $29313.78.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Haddadin Yezan Munther bought 1,882 shares, generating $22,242 in total proceeds. Upon buying the shares at $11.82, the Director now owns 5,049 shares.
Before that, Evanson Jeff bought 62,484 shares. Outlook Therapeutics Inc shares valued at $26,243 were divested by the CHIEF COMMERCIAL OFFICER at a price of $0.42 per share. As a result of the transaction, Evanson Jeff now holds 808,459 shares, worth roughly $3.99 million.
BTIG Research upgraded its Outlook Therapeutics Inc [OTLK] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Chardan Capital Markets’s analysts, who increased its forecast for the stock in mid February from “a Neutral” to “a Buy”. Guggenheim also remained covering OTLK and has increased its forecast on January 25, 2024 with a “Buy” recommendation from previously “Neutral” rating. CapitalOne revised its rating on December 27, 2023. It rated OTLK as “an Overweight” which previously was an “an Equal weight”.
Price Performance Review of OTLK
On Monday, Outlook Therapeutics Inc [NASDAQ:OTLK] saw its stock fall -1.99% to $4.93. Over the last five days, the stock has lost -4.36%. Outlook Therapeutics Inc shares have fallen nearly -37.44% since the year began. Nevertheless, the stocks have fallen -46.41% over the past one year. While a 52-week high of $12.85 was reached on 04/01/24, a 52-week low of $4.61 was recorded on 10/10/24. SMA at 50 days reached $5.56, while 200 days put it at $7.34.
Levels Of Support And Resistance For OTLK Stock
The 24-hour chart illustrates a support level at 4.84, which if violated will result in even more drops to 4.75. On the upside, there is a resistance level at 5.10. A further resistance level may holdings at 5.27. The Relative Strength Index (RSI) on the 14-day chart is 34.14, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.68, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.51%. Stochastics %K at 2.54% indicates the stock is a buying.
How much short interest is there in Outlook Therapeutics Inc?
A steep rise in short interest was recorded in Outlook Therapeutics Inc stocks on 2024-10-31, growing by 0.28 million shares to a total of 3.23 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 2.95 million shares. There was a rise of 8.69%, which implies that there is a positive sentiment for the stock.
